Page last updated: 2024-08-24

ziprasidone and Movement Disorders

ziprasidone has been researched along with Movement Disorders in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Campbell, EC; Caroff, SN; Chakos, MH; Davis, SM; Davis, VG; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, DD; Riggio, S; Rosenheck, RA; Saltz, BL; Stroup, TS; Swartz, MS1
Murray, S; OliƩ, JP; Spina, E; Yang, R1
Harrigan, EP; Keck, PE; Reeves, KR1

Trials

3 trial(s) available for ziprasidone and Movement Disorders

ArticleYear
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Movement Disorders; Olanzapine; Perphenazine; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome

2011
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    International clinical psychopharmacology, 2006, Volume: 21, Issue:3

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Behavioral Symptoms; Double-Blind Method; Female; Hospitalization; Humans; Ketones; Male; Middle Aged; Movement Disorders; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome; Weight Gain; Weight Loss

2006
Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Movement Disorders; Piperazines; Psychotic Disorders; Thiazoles; Treatment Outcome

2001